Incorporating Individual-Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations.
Pubmed ID: 39136305
Pubmed Central ID: PMC11963924
Journal: Journal of the American Heart Association
Publication Date: Aug. 20, 2024
MeSH Terms: Humans, Male, Female, Aged, Middle Aged, Hypertension, Risk Assessment, Treatment Outcome, Blood Pressure, Antihypertensive Agents, Precision Medicine, Patient Preference, Decision Making, Shared, Health Planning Guidelines
Grants: UL1 TR000445, UL1 TR000005, HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, P30 GM103337, UL1 TR000433, UL1 TR000439, UL1 TR000002, UL1 TR001064, UL1 TR000064, UL1 TR000075, UL1 RR025752, UL1 RR025771, UL1 TR000093, UL1 TR000003, UL1 TR000050, UL1 TR000073, UL1 RR025755, UL1 TR000105, UL1 RR024134, K24 DK110427, R01 DK098234, UL1 TR001420, KL2 TR001859
Authors: Shlipak MG, Berry JD, Tancredi DJ, de Lemos JA, Killeen AA, Ix JH, Estrella MM, Ascher SB, Kravitz RL, Scherzer R
Cite As: Ascher SB, Kravitz RL, Scherzer R, Berry JD, de Lemos JA, Estrella MM, Tancredi DJ, Killeen AA, Ix JH, Shlipak MG. Incorporating Individual-Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations. J Am Heart Assoc 2024 Aug 20;13(16):e033995. Epub 2024 Aug 13.
Studies:
Abstract
BACKGROUND: There are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences. METHODS AND RESULTS: Among 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0-5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2-2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs (<i>P</i><0.001 in both simulations). CONCLUSIONS: Most SPRINT participants had a predicted net benefit that favored intensive BP lowering, but the degree of net benefit varied considerably. Tailoring BP targets using each patient's risks and preferences may provide more refined BP target recommendations.